Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Hopes Kyprolis Label Expansion Will Give It A Leg Up In The Myeloma Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm believes addition of data from the ENDEAVOR trial, and new claims, will establish the proteasome inhibitor as a backbone of choice across lines of therapy.

Advertisement

Related Content

Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079036

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel